Biomaterial Database

Current Status of Newborn Screening in Southeastern Europe. 2021

Vanesa Koracin, and Matej Mlinaric, and Ivo Baric, and Ian Brincat, and Maja Djordjevic, and Ana Drole Torkar, and Ksenija Fumic, and Mirjana Kocova, and Tatjana Milenkovic, and Florentina Moldovanu, and Vjosa Mulliqi Kotori, and Michaela Iuliana Nanu, and Ziga Iztok Remec, and Barbka Repic Lampret, and Dimitrios Platis, and Alexey Savov, and Mira Samardzic, and Biljana Suzic, and Ildiko Szatmari, and Alma Toromanovic, and Mojca Zerjav Tansek, and Tadej Battelino, and Urh Groselj

General Hospital Novo mesto, Novo mesto, Slovenia.

Significant part of Southeastern Europe (with a population of 76 million) has newborn screening (NBS) programs non-harmonized with developed European countries. Initial survey was conducted in 2013/2014 among 11 countries from the region (Albania, Bulgaria, Bosnia and Herzegovina (BIH), Croatia, Kosovo, Macedonia, Moldova, Montenegro, Romania, Serbia, and Slovenia) to assess the main characteristics of their NBS programs and their future plans. Their cumulative population at that time was ~52,5 million. At that time, none of the countries had an expanded NBS program, while phenylketonuria screening was not introduced in four and congenital hypothyroidism in three of 11 countries. We repeated the survey in 2020 inviting the same 11 countries, adding Cyprus, Greece, Hungary, and Malta (due to their geographical position in the wider region). The aims were to assess the current state, to evaluate the change in the period, and to identify the main obstacles impacting the implementation of expanded NBS and/or reaching a wider population. Responses were collected from 12 countries (BIH-Federation of BIH, BIH-Republic of Srpska, Bulgaria, Croatia, Greece, Hungary, Kosovo, North Macedonia, Malta, Montenegro, Romania, Serbia, Slovenia) with a population of 68.5 million. The results of the survey showed that the regional situation regarding NBS only modestly improved in this period. All of the surveyed countries except Kosovo screened for at least congenital hypothyroidism, while phenylketonuria was not screened in four of 12 countries. Croatia and Slovenia implemented an expanded NBS program using tandem mass spectrometry from the time of last survey. In conclusion, the current status of NBS programs in Southeastern Europe is very variable and is still underdeveloped (or even non-existent) in some of the countries. We suggest establishing an international task-force to assist with implementation and harmonization of basic NBS services where needed.